Hematology
Conference Coverage
Factor XI inhibitor–based anticoagulation strategies gain ground
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
From the Journals
COVID-19: Thromboembolic events high despite prophylaxis
“Standard prophylaxis as recommended in the guidelines is a low dose of low-molecular-weight...
From the Journals
INR fails to predict bleeding in patients with cirrhosis
The investigators hope the study findings reinforce minimizing administration of fresh frozen plasma for inappropriate correction of international...
Latest News
Convalescent plasma: ‘Flavor of the month’ or valid COVID-19 treatment?
“The special attraction of this modality of treatment is that, unlike vaccines or newly developed drugs, it could, in principle, be made available...
Feature
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
From the Journals
Inflammation, thrombosis biomarkers tied to COVID-19 deaths
“Of particular interest is the finding that over three quarters of critically ill patients required a ventilator and almost one third required...
News
COVID-19–associated coagulopathy
Early recognition and anticoagulation is imperative to improve clinical outcomes in COVID-19–associated coagulopathies.
From the Journals
COVID-19 pulmonary severity ascribed to coagulation differences
Feature
EHA and TIF explore how COVID-19 is affecting thalassemia and SCD patients
Feature
Can convalescent plasma treat COVID-19 patients?
How COVID-19 patients can receive convalescent plasma, who is eligible to donate, and early results of treatment.
News from the FDA/CDC
FDA okays emergency use of convalescent plasma for seriously ill COVID-19 patients
“It’s crucial that data be captured for every patient so that we really understand what safety and effectiveness looks like on as close to a real-...